COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Jan 9, 2023

Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Peripheral T-cell Lymphoma

Feb 9, 2022

Secura Bio Announces Final Patient Enrolled in the COPIKTRA (duvelisib) (PRIMO) Study in Relapsed and Refractory Peripheral T-cell Lymphoma

Dec 14, 2021

SECURA BIO ANNOUNCES THE PRESENTATION OF NEW COPIKTRA (duvelisib) DATA FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS (PTCL).

Dec 6, 2021

Secura Bio Announces New Data To Be Presented At The American Society Of Hematology

Dec 3, 2021

Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication

For More Press Releases

---